gripe e sinusite.Em ensaios clinicos em edema maculardiabetico, os efeitos colaterais oculares mais comuns incluiram hemorragiaconjuntival, catarata, aumento da pressao intra-ocular e descolamento dovitreo. Os efeitos secundariosnao oculares mais comuns incluiram nasofaringite, anemia e nausea.Tal como acontece com todas as proteinasterapeuticas, existe o potencial para uma resposta imune em pacientes tratadoscom LUCENTIS. O significadoclinico da imunorreatividade para Lucentis e claro neste momento.Para obterinformacoes de seguranca adicionais, consulte LUCENTISinformacoes prescricao total .Referencias: 1. Lucentis [bula]. South San Francisco, CA: Genentech,Inc; 2013. 2. Busbee BG, Ho AC, Brown DM, et al, poiso Grupo de Estudos sobre o porto. Eficaciae seguranca de 0,5 mg ou 2,0 mg de ranibizumab em pacientes com degeneracaosubfoveal neovascular macular relacionada a idade [publicado online ahead ofprint 23 de janeiro de 2013] doze meses. Oftalmologia . doi:10.1016/j.ophtha.2012.10.014.O Fator de crescimento do endotelio vascular(VEGF) desempenha um papelimportante na fisiopatologia da visao em risco varios disturbios da retina comoa degeneracao macular relacionada a idade, edema macular diabetico eretinopatia diabetica proliferativa. A descoberta de agentes anti-VEGF temrevolucionado o tratamento dessas condicoes. Existem 4 agentes anti-VEGF quetambem sao aprovados ou de usam comum em oftalmologia, nomeadamente opegaptanib (Macugen, Pfizer), o ranibizumab (Lucentis, Novartis), afliberceptou VEGF Trap-olho (EYLEA, Bayer) e bevacizumab (Avastin, Roche)Vascularendothelial growth factor promotes progressive retinal nonperfusion in patientswith retinal vein occlusion.Campochiaro,P.A.; Bhisitkul, R.B.; Shapiro, H.; Rubio, R.G.Ophthalmology Vol. 120 Nr. 4 Pagina: 795 - 802 Data da publicacao:01/04/2013Resumo:OBJECTIVE: Central retinalvein occlusion (CRVO) or branch retinal vein occlusion (BRVO) causeshypoperfusion, high levels of vascular endothelial growth factor (VEGF),macular edema, and loss of vision. Many patients also show areas of completeclosure of retinal vessels (retinal nonperfusion [RNP]) that increase overtime. The objective was to assess the effect of blocking VEGF on progression ofRNP. DESIGN: Retrospective analysis of prospectively collected data from 2randomized, sham injection-controlled, double-masked, multicenter clinicaltrials. PARTICIPANTS: A total of 392 and 397 patients with macular edema due toCRVO or BRVO. METHODS: An independent reading center measured the area of RNPon fluorescein angiograms (FAs) in 2 phase III trials investigating the effectof ranibizumab (RBZ; Lucentis; Genentech, Inc, South San Francisco, CA) inpatients with CRVO or BRVO. MAIN OUTCOME MEASURES: The percentage of patientswith no posterior RNP at months 0, 3, 6, 9, and 12. RESULTS: There was nodifference among treatment groups at baseline, but at the month 6 primary endpoint the percentage of patients with CRVO and no RNP was significantly greaterin the RBZ groups (0.3 mg, 82.0%, P = 0.0092; 0.5 mg, 84.0%, P = 0.0067) versusthe sham group (67.0%). Reperfusion of nonperfused retina was rare (1%) insham-treated patients with CRVO, but occurred in 6% to 8% of patients with CRVOtreated with RBZ (30% of those who had RNP and could improve). Results inpatients with BRVO mirrored those in patients with CRVO. Crossover to 0.5 mgRBZ from sham at month 6 halted the progression of RNP and resulted inimprovement in both CRVO and BRVO. CONCLUSIONS: Treatment with RBZ did notworsen RNP in patients with RVO, but rather reduced its occurrence comparedwith sham. These data provide an important new insight regarding thepathogenesis of RVO; the initial vein occlusion is a precipitating event thatcauses